New Weight Loss Medications in 2026: What Patients Should Know

By Michaela Mocanu, MD, DABOM — obesity medicine specialist and nephrologist at Main Line Kidney & Primary Care in Haverford, PA

Weight loss medications have changed more in the past year than in the previous decade. There are now two FDA-approved weight loss pills, a higher-dose Wegovy shot, and, since July 2026, Medicare coverage of GLP-1 medications for a $50 copay.

I recently attended a national obesity medicine workshop led by Dr. Caroline Apovian of Harvard Medical School. Here is what matters most right now for patients in Haverford, on the Main Line and across the Philadelphia area.

Is obesity a disease? Why willpower isn't the problem

Your brain — especially an area called the hypothalamus — works like a thermostat for body fat. It uses hormones from your gut and fat tissue to decide how hungry you feel and how much energy to burn. In obesity, that system is set to defend a higher weight.

This is why diets alone so often fail. In one well-known study, people who lost weight through diet still had higher hunger hormones and lower fullness hormones a full year later.² Their bodies were actively pushing them to regain. That isn't a personal failing. It's biology, and it's why medical treatment can help.

How much weight loss do you need to improve your health?

Benefits start early:

• 5% weight loss (10 lb for a 200 lb person) can improve blood pressure, blood sugar and cholesterol.
• 10–15% helps with fatty liver, sleep apnea, acid reflux, knee pain and diabetes prevention.
• 15% or more can put type 2 diabetes into remission and lowers heart risk.

Obesity is linked to more than 100 conditions, including heart disease, kidney disease, diabetes and several cancers.³ Treating the weight first can improve many of them at once.

Weight loss medications in 2026: GLP-1 shots and pills compared

GLP-1 medications such as semaglutide (Wegovy) and tirzepatide (Zepbound) copy natural gut hormones (GLP-1, and for tirzepatide also GIP). They help you feel full sooner, quiet "food noise" and steady blood sugar.

Medication	How it's taken	Average weight loss in studies
Zepbound (tirzepatide)	Weekly injection	About 20–22%4
Wegovy HD (semaglutide 7.2 mg), new March 2026	Weekly injection, after the standard dose	About 21%5
Wegovy (semaglutide 2.4 mg)	Weekly injection	About 15–17%6
Wegovy pill (oral semaglutide), new January 2026	Daily pill	About 14–17%7
Foundayo (orforglipron), new April 2026	Daily pill, no food or water rules	About 11–12%8
Older options (phentermine, Qsymia, Contrave)	Pills	About 5–10%3

The big news this year: weight loss pills. If you've avoided treatment because you don't want injections, there are now two daily tablets. Foundayo can be taken any time of day, with or without food. The Wegovy pill has stricter timing around meals but produces somewhat more weight loss.

The most common side effects are nausea, constipation, diarrhea and reflux, usually early on and when the dose goes up. We start low and increase slowly to keep these manageable. These medicines aren't for everyone: they are not used during pregnancy or in people with certain thyroid cancers, and we'll review your history together.

Health benefits of GLP-1 medications beyond weight loss

Large studies now show these medicines protect organs, not just reduce weight:

• Heart: Wegovy lowered the risk of heart attack, stroke and heart-related death by 20% in people with existing heart disease, and is FDA-approved for that purpose.⁹
• Diabetes prevention: In the same study, the risk of developing diabetes fell by about 73%.⁹
• Kidneys: In people with type 2 diabetes and chronic kidney disease, semaglutide slowed kidney decline and reduced kidney- and heart-related deaths by 24%.¹⁰ For many of our kidney patients, this is a real step forward.
• Heart failure: People with a common type of heart failure (preserved ejection fraction) had fewer symptoms and could do more.¹¹
• Blood pressure, sleep apnea and fatty liver also improve. Zepbound is approved for sleep apnea¹² and Wegovy for a form of fatty liver disease.¹³

Do you have to stay on Wegovy or Zepbound long-term?

When people stop these medications, weight usually comes back. In a major tirzepatide study, people who switched to placebo after 9 months regained about 14% of their weight over the next year, while those who stayed on it kept losing.¹⁴

That doesn't mean you can never adjust or lower a dose. It means we plan for the long term together, the same way we would for diabetes or high blood pressure.

Diet and exercise on GLP-1 medications: protecting your muscle

Medication works best alongside lifestyle changes. While you're losing weight, we want to protect your muscle:

• Eat enough protein at each meal.
• Do strength training at least 2 days a week, plus about 150 minutes of walking or other activity.
• Pick an eating pattern you can actually stick with. There's no single "right" diet.

Does Medicare cover weight loss medications in 2026?

• Medicare now covers weight-loss medications. Since July 1, 2026, Medicare's GLP-1 Bridge program covers Wegovy (shot and pill), Zepbound and Foundayo for a $50 monthly copay, through the end of 2027.¹⁶ You need a Part D or Medicare Advantage drug plan and must meet certain criteria — for example a BMI of 35 or more, or a lower BMI with conditions such as uncontrolled high blood pressure, chronic kidney disease, heart failure, prediabetes, or a prior heart attack or stroke. We submit the prior authorization for you.
• Lower cash prices. Without insurance, starting doses of the new pills begin around $149 a month, and manufacturer self-pay programs for the injections have dropped well below past list prices.
• Commercial insurance varies widely. Call us and we'll help you check your plan.

Is compounded semaglutide or tirzepatide safe?

The drug shortages that allowed pharmacies to make copies of semaglutide and tirzepatide ended in 2025. The FDA has since received well over 1,700 reports of side effects linked to compounded versions, including dosing errors that led to hospital stays.¹⁷

Please avoid products sold online as "research only" or "not for human use," and anything labeled retatrutide or CagriSema. Those drugs are not approved and cannot legally be sold. With today's lower prices for the approved medicines, there are safer options.

New obesity drugs coming soon: CagriSema and retatrutide

• CagriSema (semaglutide plus a second hormone, amylin): an FDA decision is expected in late 2026.¹⁸
• Retatrutide (a "triple" hormone shot): showed more than 20% weight loss in large studies; the company plans to apply for approval in early 2027.¹⁹
• Researchers are also working on medicines that help preserve muscle during weight loss.

Weight loss surgery vs. medication

Weight-loss (metabolic) surgery remains the most effective long-term treatment, with about 25–30% weight loss and high rates of diabetes improvement.²⁰ Guidelines now consider it starting at a BMI of 35, or 30 with diabetes or metabolic disease.²¹ Medication and surgery aren't either/or; some patients benefit from both.

Frequently asked questions

What is the newest weight loss medication in 2026? Foundayo (orforglipron), a once-daily pill the FDA approved in April 2026. Wegovy HD, a higher 7.2 mg dose of the Wegovy shot, was approved in March 2026.

Is there a weight loss pill that works like Wegovy? Yes. The Wegovy pill contains the same medicine (semaglutide) as the shot. Foundayo (orforglipron) works on the same receptor but is a different molecule — a small oral tablet with no food or water restrictions.

Which works better, Wegovy or Zepbound? On average, Zepbound (tirzepatide) produces more weight loss: about 20–22%, compared with 15–17% for standard-dose Wegovy. Wegovy has proven heart-protection benefits. The best choice depends on your health conditions, side effects and cost.

How much does Medicare charge for Wegovy or Zepbound? Eligible patients pay $50 a month through Medicare's GLP-1 Bridge program, which runs through December 31, 2027.

Will I regain weight if I stop a GLP-1 medication? Most people regain some weight after stopping. We plan for long-term treatment and adjust doses over time.

Obesity medicine care in Haverford and the Main Line

There has never been a better time to treat weight as the medical condition it is. Options are more effective, easier to take, and more affordable than even a year ago.

If you'd like to talk about whether treatment is right for you, or you're already on a medication and have questions about cost or coverage, please schedule a visit at our Haverford office or by telemedicine. Email contact@weightkidneycare.com to request an appointment. Bring your current medication list and, if you have Medicare, your Part D card.

— Dr. Michaela Mocanu, MD, DABOM

---

This article is for general education and isn't a substitute for personal medical advice. Medication prices and coverage rules change often; information is current as of October 2026.

References

1. Apovian CM. Obesity treatment – medical and surgical (Workshop A.2: Pharmacologic Management of Obesity in 2026). Conference workshop presentation. 2026.
2. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011. https://doi.org/10.1056/NEJMoa1105816
3. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016. https://doi.org/10.4158/EP161365.GL
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. https://doi.org/10.1056/NEJMoa2206038
5. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025. https://doi.org/10.1016/S2213-8587(25)00099-5
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. https://doi.org/10.1056/NEJMoa2032183
7. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine. 2025. https://doi.org/10.1056/NEJMoa2501557
8. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine. 2025. https://doi.org/10.1056/NEJMoa2502038
9. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023. https://doi.org/10.1056/NEJMoa2307563
10. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2024. https://doi.org/10.1056/NEJMoa2403347
11. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. 2023. https://doi.org/10.1056/NEJMoa2306963
12. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. 2024. https://doi.org/10.1056/NEJMoa2404881
13. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. New England Journal of Medicine. 2025. https://doi.org/10.1056/NEJMoa2413258
14. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. https://doi.org/10.1001/jama.2023.24945
15. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 2023. https://doi.org/10.1038/s41591-023-02597-w
16. American Medical Association. CMS releases physician guidance on new Medicare GLP-1 Bridge Program. AMA Advocacy Update. 2026. https://www.ama-assn.org/practice-management/medicare-medicaid/cms-releases-physician-guidance-new-medicare-glp-1-bridge-program
17. FDA warns clinicians on compounded GLP-1s amid 1,700+ safety reports. Becker's Hospital Review. 2026. https://www.beckershospitalreview.com/pharmacy/fda-warns-clinicians-on-compounded-glp-1s-amid-1-700-safety-reports.html
18. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025. https://doi.org/10.1056/NEJMoa2410406
19. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. News release. 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional-phase
20. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. Journal of Internal Medicine. 2013. https://doi.org/10.1111/joim.12012
21. Eisenberg D, Shikora SA, Aarts E, et al. 2022 ASMBS and IFSO indications for metabolic and bariatric surgery. Surgery for Obesity and Related Diseases. 2022. https://doi.org/10.1016/j.soard.2022.08.013